IPI were available only in 116/215 samples analyzed. PIK3CA mutations were associated with a higher IPI score although this was not statistically significant (P ¼ 0.0834), which might be attributed to the relatively small number of DLBCL cases that were positive for the PIK3CA mutation. In addition, it was significantly associated with involvement of more than one extra nodal site (P ¼ 0.0497) and with tumor stage (P ¼ 0.0103). As a read out of PIK3CA functional activation, we tested AKT phosphorylation in DLBCL by IHC. Virtually all of the samples harboring PIK3CA mutations showed some staining (scored þ 1 to þ 3) for p-AKT (17 out of the 17 cases). However, only 10 of the 17 (59%) mutated cases showed increased p-AKT level by IHC (defined as DLBC samples scored as þ 2 or þ 3). 5 Furthermore, our findings that PIK3CA mutations correlate with tumor stage, suggest that increased PIP3 production and activation of PI3K/AKT may enhance tumor progression. PIK3CA mutations showed association with the non-germinal-activated B-cell type subtype, although this association was not statistically significant (P ¼ 0.074).
Furthermore, our findings that PIK3CA mutations correlate with tumor stage, suggest that increased PIP3 production and activation of PI3K/AKT may enhance tumor progression. PIK3CA mutations showed association with the non-germinal-activated B-cell type subtype, although this association was not statistically significant (P ¼ 0.074).
Given the significant association of PIK3CA mutations to two clinical markers (tumor stage and involvement of more than one extra nodal site) we performed survival analysis. No significant associations were found between PIK3CA mutational status and overall survival within DLBCL patients. We further stratified all our DLBCL cases into two groups depending on the presence of PIK3CA mutation and PTEN expression status: normal PIK3CA and normal PTEN (n ¼ 114) and DLBCL with either mutated PIK3CA or absent/reduced PTEN expression (n ¼ 91). Such a stratification showed a significant correlation with 10-year overall survival (P ¼ 0.0249) and remained significant even in multivariate analysis that included IPI, stage, number of extranodal sites and the above mentioned two groups. The relative risk for death was 1.9 for the DLBCL group with abnormal PIK3CA or PTEN (95% CI 1.2-2.9, P ¼ 0.0017) and 2.4 for high-risk IPI group (95% CI 1.4-4.2, Po0.0011).
To our knowledge, this is the first report on the presence of PIK3CA mutations in DLBCL patients. Furthermore, the ability to stratify DLBCL patient outcome based on the deregulation of PIP3 production gives further support of putative role of PI3K pathway in the regulation of DLBCL progression, which makes this pathway an attractive target for pharmacologic interventions. In particular, directed small molecule antagonism of PIK3CA proteins may be an effective measure for the treatment of DLBCL. Altogether, our study shows that a large proportion of DLBCL have either an inactivation of PTEN or activation of PIK3CA and this group is associated with poor overall survival. This loss of PIP3 homeostasis due to PTEN inactivation and PIK3CA activation in DLBCLs is remarkably similar to that reported in other human cancers. These findings indicate that mutation in PIK3CA is likely to function as an oncogene in DLBCL and argue for the role of PIK3CA targeting in the treatment of DLBCL patients.
11q23 may house several genes that are important for the process of leukemogenesis. Structural aberrations involving 11q are among the most common aberrations in a number of hematological malignancies and often harbor a breakpoint at 11q23. 1 One of the common aberrations is deletion, that is associated with a poor clinical outcome. 2 Chromosome deletion suggests that the region might contain at least a tumor suppressor gene important for the genesis of lymphoproliferative disorders. 3, 4 Investigating cancer-specific methylation is a preferential approach for identifying genes that are important in cancer development. 5 There have been few reports regarding methylation involving 11q23 in leukemia. Therefore, we further investigated whether, in leukemia, there exists a gene that is controlled by the epigenetic modification in this region.
We screened several candidate genes on chromosome 11q23, 3 for example, ZW10, NCAM1, ANKK1 and tetratricopeptide repeat (TPR) domain 12 (TTC12), by combined bisulfite restriction analysis (COBRA) assay 6 ( Figure 1 ). TTC12 is located in between NCAM1 and ANKK1 (www.ncbi.nlm.nih.gov). We examined the methylation status of CpG dinucleotides around the 5 0 end from the transcriptional start site. Treatment with bisulfite converts unmethylated cytosines, but not methylated cytosines, to uracils and then thymines after PCR. 7 This generates detectable methylation-dependent changes in the restriction pattern of PCR-amplified sequences from CCGA to TCGA in case of methylation and TTGA in case of nonmethylation. Whereas methylation levels of ZW10, NCAM1 and ANKK1 in leukemic cell lines were none to partial (Figure 1a) , TTC12
8 was shown to be hypermethylated in several leukemic cell lines (Figure 1b) .
We investigated if TTC12 methylation is directly correlated with the inhibition of expression in leukemia. Hypermethylation was demonstrated in all leukemic cells, except K562, (Figure 1b) . In contrast, epithelial cells were not methylated (Figure 1b) . The cDNA was amplified by PCR and real-time PCR with the TTC12-RT primers, TGGGCGAATCAGGGATTCC and GCATTCATCCTCCTCCTGGT, and the GAPDH primers, GTGGGCAAGGTATCCCTG and GATTCAGTGTGGTGGGG GAC. GAPDH was used as control and to calculate the relative quantity of TTC12 mRNA. Non-methylated and hypermethylated cell lines expressed and did not express TTC12 mRNA levels, respectively (Figure 1b) .
Furthermore, we evaluated 30 bone marrow samples from acute lymphoblastic leukemia (ALL) cases, normal white blood cells (WBC) from 10 healthy volunteers and eight samples of complete remission bone marrows. The ALL diagnosis was based on the criteria of the World Health Organization (WHO) classification of tumors. All bone marrows were subjected to immunophenotyping and immunomagnetic selection. 9 The Figure 1 TTC12 methylation and expression in cell lines and leukemia. Molt4 (acute lymphoblastic leukemia), Daudi (B lymphoblastoid line), Jurkat (acute T-cell leukemia), HeLa (cervical cancer), HN12 (head and neck squamous cell cancer), K562 (chronic myelogenous leukemia) and SW480 (stomach cancer) were investigated. Whereas no methylation or only partial methylation levels of ZW10, NCAM1 and ANKK1 were detected in leukemic cell lines, TTC12 was hypermethylated. In leukemia, TTC12 was methylated and showed a decrease in expression. results indicated the association between epigenetic regulation and leukemogenesis. While in normal WBC TTC12 was hypomethylated, hypermethylated TTC12 was usually detectable in ALL (Po0.0001; Figures 1c and 2a) . Whereas the mean and the highest methylation levels were, respectively, 9.42 and 11.63% in WBC and 5.12 and 6.62% in remission bone marrow, the mean TTC12 methylation in ALL was 56.33%. In addition, 93% of all ALL cases showed methylation levels higher than 12% (Figure 2a) .
Methylation of a gene is directly correlated with the inhibition of expression in ALL. Higher expression of TTC12 was also detectable in WBC (Figures 1c and 2b) . We categorized ALL into two groups as hypermethylated and hypomethylated TTC12, depending on the level of methylation in relation the mean methylation level (56.33%). The mRNA level of hypermethylated ALL was less than in hypomethylated ALL (Po0.05; Figure 2b ). In conclusion, TTC12 methylation associated with leukemogenesis, and methylation may be important in this gene inactivation.
We further confirm and characterize the TTC12 methylation status by cloning and sequencing hypomethylated, partially methylated and hypermethylated COBRA amplicons from ALL (Figure 2c) . Methylation of the CpG island was directly correlated with methylation levels of COBRA. We re-evaluated the methylation status of TTC12 at 408 bp, 5 0 end from the previous COBRA, by TT(C/T)GATTTTGGTTTTTAATTTGG and AAC(G/A)AAACCAAAAACCAAAAACC, generating 187 bp methylation-dependent BstUI-digestible amplicons, and compared the methylation levels with the previous COBRA. The methylation levels from both locations were directly associated (P ¼ 0.0004; Pearson r ¼ 0.7974). This confirmed the previous COBRA results.
This study shows that the TTC12 gene was specifically hypermethylated in ALL. Moreover, TTC12 expression was inhibited in association with the epigenetic modification. Therefore, depletion of TTC12 activity may be important for the process of leukemogenesis. Although the function of TTC12 has not been identified, in silico, two conserved domains have been found, including the TPR and the armadillo repeat (ARM) domains. 8 Both ARM and TPR are implicated in a variety of cellular processes, ranging from cell cycle control to signal transduction, kinase regulation and tumorigenesis. Therefore, downregulation of TTC12 may contribute to the promotion of a multistep process of ALL. Further investigations will provide new knowledge of hematologic malignancy biology that could be applied to diagnosis as well as therapeutic modalities.
